Clovertex’s April 2025 Target of the Month is the neonatal Fc receptor (FcRn), following the U.S....
Clovertex’s May Target of the Month is B-Raf, a serine/threonine kinase that plays a central role in the MAPK signaling pathway, regulating cell growth and survival. Mutations in B-Raf, particularly the V600E variant, are well-known drivers of several aggressive cancers, including a subset of metastatic colorectal cancers (mCRC), which affect around 8–12% of mCRC patients and are associated with poor prognosis.
This month’s spotlight follows a major development: Pfizer announced that its BRAFTOVI® (encorafenib) combination regimen, used alongside cetuximab and mFOLFOX6 chemotherapy, halved the risk of death in treatment-naïve patients with B-Raf V600E-mutant mCRC compared to standard chemotherapy. These results, presented at the 2025 ASCO Annual Meeting and published in the New England Journal of Medicine, represent a significant advancement in precision oncology and reinforce the critical role of targeted therapies in improving outcomes for patients with historically limited options.
The Protein Imager rendering displays the Cryo-EM Structure of the BRAF V600E monomer (PDB entry 8VYP).
About Clovertex
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
Useful links
1. Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
2. Clovertex website
